Citations

Showing 10 of 108162 citations.

Macroscopic hematuria in wasp sting patients: a retrospective study
Wang, Maohe, Prince, Singh, Tang, Yong, Zhong, Xiang, Chen, Shasha, Li, Guisen , Wang, Li, Wang, Wei, Singh, Prince , Wang, Maohe, Prince, Singh, Tang, Yong, Zhong, Xiang, Chen, Shasha, Li, Guisen , Wang, Li, Wang, Wei

Mayo Clinic

Renal Failure | March 12, 2021 | Volume: 43 | Issue: 1 | Pages: 500-509

10.1080/0886022x.2021.1896547 | PMID 33706645 Get It

The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance
Castillo, Jorge J. , Callander, Natalie S. , Baljević, Muhamed , Sborov, Douglas W. , Kumar, Shaji , Castillo, Jorge J , Callander, Natalie

Mayo Clinic

American Journal of Hematology | March 12, 2021 | Volume: 96 | Issue: 7 | Pages: 846-853

10.1002/ajh.26155 | PMID 33709474 Get It

Abstract Despite the benign nature of monoclonal gammopathy of undetermined significance (MGUS), mounting data are associating MGUS with the development of organ dysfunction, specifically monoclonal gammopathy of renal significance (MGRS) and monoclonal gammopathy of neurological significance (MGNS), which could be associated with substantial morbidity. Emerging evidence suggests that patients with MGRS and MGNS could benefit from treatments used for myeloma, Waldenström macroglobulinemia, or chronic lymphocytic leukemia, depending on the underlying pathology. However, the treatment of MGRS and MGNS is not standardized, and potentially effective therapies might not be reimbursed because these conditions do not formally meet the criteria for malignant processes. The present review aims at establishing standards for the evaluation and management of MGRS and MGNS, which can facilitate the diagnosis of and provide therapeutic options for treating practitioners and patients affected by these conditions. The careful design and execution of clinical trials for patients with MGRS and MGNS are positively encouraged.
The value of repeated CT in monitoring the disease progression in moderate COVID-19 pneumonia
Gao, Yang , Hu, Yuxiong, Zhu, Junteng, Qiu, Rongxian , Lin, Qunying , He, Xiongzhi, Lin, Haibin , Cheng, Shiming , Li, Guangxi , Liu, Huan , Qiu, Rongxian

Mayo Clinic

Medicine | March 12, 2021 | Volume: 100 | Issue: 10 | Pages: e25005

10.1097/md.0000000000025005 | PMID 33725880 Get It

Abstract The role of thoracic CT (computerized tomography) in monitoring disease course of COVID-19 is controversial. The purpose of this study is to investigate the risk factors and predictive value of deterioration on repeatedly performed CT scan during hospitalization. All COVID-19 patients treated in our isolation ward, from January 22, 2020 to February 7, 2020, were reviewed. Patients included were categorized into RD (Radiological Deterioration) group or NRD (No Radiological Deterioration) group according to the manifestation on the CT routinely performed during the hospitalization. All clinical data and CT images were analyzed. Forty three patients were included in our study. All are moderate cases with at least 4 CT scans each. Eighteen (42.9%) patients had radiological deteriorations which were all identified in CT2 (the first CT after admission). Patients in RD group had lower leukocyte count (P = .003), lymphocyte count (P = .030), and higher prevalence (P = .012) of elevated C-reactive protein (CRP) at admission. NRD patients had a lower prevalence of reticulations (P = .034) on baseline CT (CT1, performed within 2 days before admission) and a longer duration between symptom onset and the time of CT2 (P < .01). There was no significant difference in hospital stay or fibrotic change on CT4 (follow-up CT scan performed 4 weeks after discharge) between 2 groups. Shorter duration between symptom onset and CT2 time (odds ratio [OR], 0.436; 95% confidence interval: 0.233–0.816; P < .01) and lower leukocyte count in baseline evaluation (OR, 0.316; 95% CI: 0.116–0.859; P < .05) were associated with increased odds of radiological deterioration on CT image during hospitalization. For moderate COVID-19 patients, the value of routinely performed CT during the treatment is limited. We recommend avoiding using CT as a routine monitor in moderate COVID-19 patients.
User-centered design and development of a trunk control device for persons with spinal cord injury: A pilot study
Looft, John M. , Sjoholm, Robert, Hansen, Andrew H. , Fairhurst, Stuart, Voss, Greg, Dellamano, Clifford A., Egginton, Jason S. , Olney, Christine M. , Goldish, Gary D, Egginton, Jason, Olney, Christine

Mayo Clinic

The Journal of Spinal Cord Medicine | March 12, 2021 | Volume: 45 | Issue: 4 | Pages: 585-594

10.1080/10790268.2020.1863897 | PMID 33705266 Get It

Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma
Sun, Guangxi , Liang, Jiayu, Yin, Xiaoxue , Zhang, Mengni , Yao, Jin , He, Ning , Armstrong, Cameron M. , Zheng, Linmao , Sun, Xiaomeng , Yang, Xiaoxia , Zhao, Wanbin , Liao, Banghua , Pan, Xiuyi , Yang, Ling , Zhao, Jinge , Dai, Jindong, Shen, Yali , Huang, Rui , Liu, Jiandong , Wang, Zhipeng , Ni, Yuchao , Wei, Qiang , Zhou, Qiao , Liu, Zhenhua , Shen, Pengfei , Chen, Ni , Zeng, Hao , Sun, Guangxi , Chen, Junru , Zhang, Xingming , Zhu, Sha , Nie, Ling , Chen, Yahong , Zhang, Haoran , Liu, Jiyan , Li, Xiang , Huang, Haojie

Mayo Clinic

No container title available | March 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-296261/v1 Get It

Abstract TFE3-translocation renal cell carcinoma (TFE3-tRCC) is a rare and heterogeneous subtype of kidney cancer that has no standard treatment for advanced disease. We described comprehensive molecular characteristics of 63 untreated primary TFE3-tRCCs based on whole-exome and RNA sequencing. TFE3-tRCC is highly heterogeneous, both clinicopathologically and genotypically. ASPSCR1-TFE3 fusion, certain fusion isoforms and high somatic copy number alteration burdens were associated with aggressive features and poor outcomes. Apart from tumors with MED15-TFE3 fusion, most TFE3-tRCCs exhibited low PD-L1 expression and low T-cell infiltration. Unsupervised transcriptomic analysis revealed five molecular clusters with distinct angiogenesis, stroma, proliferation and KRAS down signatures, which showed association with fusion patterns and prognosis. Specifically, the high angiogenesis/stroma/proliferation cluster exclusively consisted of tumors with ASPSCR1-TFE3 fusion, which was likely to benefit from combination of immune checkpoint and anti-angiogenesis inhibitors. Our findings reveal the genomic and transcriptomic features of TFE3-tRCC and provide insights into precision medicine for this disease.
Increased RV:LV Ratio on Chest CT-Angiogram in COVID-19 is a Marker of Adverse Outcomes
Tao, Ran , Buřivalová, Zuzana , Masri, Sofia Carolina , Dharmavaram, Naga , Baber, Aurangzeb , Deaño, Roderick C. , Hess, Timothy , Dhingra, Ravi , Runo, James , Jarjour, Nizar N. , Eldridge, Marlowe, Vanderpool, Rebecca , Chesler, Naomi C. , Kusmirek, Joanna E. , François, Christopher J. , Raza, Farhan

Mayo Clinic

No container title available | March 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-267902/v1 Get It

Abstract PurposeOur study aimed to use chest CT-angiogram (CTA) to assess if right ventricular (RV) dilation, quantified as an increased RV:LV (left ventricle) ratio, is associated with adverse outcomes in the novel coronavirus (COVID-19) infection.MethodsWe reviewed clinical, laboratory, and chest CTA findings in COVID-19 patients (n=100), and two control groups: normal subjects (n=10) and subjects with organizing pneumonia (n=10). On a chest CTA, we measured basal dimensions of the RV and LV in a focused 4-chamber view; and dimensions of pulmonary artery (PA) and aorta (AO) at the PA bifurcation level. ResultsAmong the COVID-19 cohort, the mean age (±SD) was 55.1±14.9 years and 55% were female. A higher RV:LV ratio was correlated with adverse outcomes, defined as ICU admission, intubation, or death. In patients with adverse outcomes, the RV:LV ratio was 1.06±0.10, vs 0.95±0.15 in patients without adverse outcomes. Among the adverse outcomes group, compared to the control subjects with organizing pneumonia, the lung parenchymal damage was lower (22.6±9.0 vs 32.7±6.6), yet the RV:LV ratio was higher (1.06±0.14 vs 0.89±0.07). In ROC analysis, RV:LV ratio had an AUC= 0.707 with an optimal cut-off of RV:LV 1.1 as a predictor of adverse outcomes. In a validation cohort (n=25), an RV:LV ≥1.1 as a cut-off predicted adverse outcomes with an odds ratio of 76:1.ConclusionIn COVID-19 patients, RV:LV ratio ≥1.1 on CTA-chest is correlated with adverse outcomes. RV dilation in COVID-19 is out of proportion to parenchymal lung damage, pointing towards a vascular and/or thrombotic injury in the lungs.
Senolytics: Potential for Alleviating Diabetes and Its Complications
Kirkland, James L. , Palmer, Allyson K. , Kirkland, James L , Tchkonia, Tamar

Mayo Clinic

Endocrinology | March 11, 2021 | Volume: 162 | Issue: 8 | Pages: No page available

10.1210/endocr/bqab058 | PMID 33705532 Get It

Abstract Therapeutics that target cellular senescence, including novel “senolytic” compounds, hold significant promise for treating or preventing obesity-induced metabolic dysfunction, type 2 diabetes, and the multiple complications of diabetes and obesity. Senolytics selectively clear senescent cells, which accumulate with aging and obesity and represent a fundamental mechanism of aging that contributes to metabolic dysfunction and diabetes pathogenesis. In addition to improving metabolic function, targeting senescent cells holds promise as a preventive strategy to reduce the incidence and severity of diabetes complications. The intermittent administration schedule used for senolytic therapy may confer benefits in terms of improving adherence and limiting adverse effects. It is necessary to design effective clinical trials that will safely translate discoveries from preclinical models into human studies that may pave the way for a novel therapeutic class for treating obesity, diabetes, and their complications. In this review, we outline what is known regarding the role of cellular senescence in the pathogenesis of type 2 diabetes and its complications, present evidence from preclinical models that targeting cellular senescence is beneficial, review senolytic drugs, and outline the features of clinical trials investigating the role of targeting senescent cells for diabetes.
Atrial fibrillation is associated with large beat-to-beat variability in mitral and tricuspid annulus dimensions
Naser, Jwan A. , Küçük, Hi̇lal Olgun , Ciobanu, A. , Jouni, Hayan, Oğuz, Didem , Thaden, Jeremy J. , Foley, Thomas A. , Eleid, Mackram F. , Naser, Jwan A , Ciobanu, Andrea O , Pislaru, Cristina , Pellikka, Patricia A. , Muraru, Denisa , Nkomo, Vuyisile T. , Pislaru, Sorin V.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | March 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ehjci/jeab033 | PMID 33724363 Get It

Abstract Aims Beat-to-beat variability in cycle length is well-known in atrial fibrillation (Afib); whether this also translates to variability in annulus size remains unknown. Defining annulus maximal size in Afib is critical for accurate selection of percutaneous devices given the frequent association with mitral and tricuspid valve diseases. Methods and results Images were obtained from 170 patients undergoing 3D echocardiography [100 (50 sinus rhythm (SR) and 50 Afib) for mitral annulus (MA) and 70 (35 SR and 35 Afib) for tricuspid annulus (TA)]. Images were analysed for differences in annular dynamics with a commercially available software. Number of cardiac cycles analysed was 567 in mitral valve and 346 in tricuspid valve. Median absolute difference in maximal MA area over four to six cycles was 1.8 cm2 (range 0.5–5.2 cm2) in Afib vs. 0.8 cm2 (range 0.1–2.9 cm2) in SR, P &lt; 0.001. Maximal MA area was observed within 30–70% of the R-R interval in 81% of cardiac cycles in SR and in 73% of cycles in Afib. Median absolute difference in maximal TA area over four to six cycles was 1.4 cm2 (range 0.5–3.6 cm2) in Afib vs. 0.7 cm2 (range 0.3–1.7 cm2) in SR, P &lt; 0.001. Maximal TA area was observed within 60–100% of the R-R interval in 81% of cardiac cycles in SR, but only in 49% of cycles in Afib. Conclusion MA and TA reach maximal size within a broad time interval centred around end-systole and end-diastole, respectively, with significant beat-to-beat variability. Afib leads to a larger beat-to-beat variability in both timing of occurrence and values of annulus size than in SR.
Quantification of Potential Inequities in Breast Cancer Incidence in New Mexico Through Bayesian Disease Mapping
Zahrieh, David , Golafshar, Michael A. , Patel, Samir H. , DeWees, T.A. , DeWees, Todd A , Golafshar, Michael

Mayo Clinic

Preventing Chronic Disease | March 11, 2021 | Volume: 18 | Issue: No issue available | Pages: No page available

10.5888/pcd18.200468 | PMID 33705303 Get It